2023
Myocardial Injury on CMR in Patients With COVID-19 and Suspected Cardiac Involvement
Vidula M, Rajewska-Tabor J, Cao J, Kang Y, Craft J, Mei W, Chandrasekaran P, Clark D, Poenar A, Gorecka M, Malahfji M, Cowan E, Kwan J, Reinhardt S, Al-Tabatabaee S, Doeblin P, Villa A, Karagodin I, Alvi N, Christia P, Spetko N, Cassar M, Park C, Nambiar L, Turgut A, Azad M, Lambers M, Wong T, Salerno M, Kim J, Elliott M, Raman B, Neubauer S, Tsao C, LaRocca G, Patel A, Chiribiri A, Kelle S, Baldassarre L, Shah D, Hughes S, Tong M, Pyda M, Simonetti O, Plein S, Han Y. Myocardial Injury on CMR in Patients With COVID-19 and Suspected Cardiac Involvement. JACC Cardiovascular Imaging 2023, 16: 609-624. PMID: 36752429, PMCID: PMC9833283, DOI: 10.1016/j.jcmg.2022.10.021.Peer-Reviewed Original ResearchConceptsCardiac magnetic resonanceNatriuretic peptide elevationMyocardial injuryIschemic patternTroponin elevationCardiac involvementChest discomfortInjury patternsCOVID-19Cardiac biomarker elevationCOVID-19 infectionAcute myocarditisAcute ischemicBiomarker elevationCardiac symptomsClinical suspicionCoronary diseaseMulticenter cohortAbnormal electrocardiogramMulticenter studyRetrospective studyECG abnormalitiesUnivariate analysisPatientsMultivariate analysis
2021
Cardiac Computed Tomography in Cardio-Oncology JACC: CardioOncology Primer
Lopez-Mattei JC, Yang EH, Ferencik M, Baldassarre LA, Dent S, Budoff MJ. Cardiac Computed Tomography in Cardio-Oncology JACC: CardioOncology Primer. JACC CardioOncology 2021, 3: 635-649. PMID: 34988472, PMCID: PMC8702811, DOI: 10.1016/j.jaccao.2021.09.010.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseSubclinical atherosclerotic cardiovascular diseaseCancer patientsPericardial diseaseCardiac CTCancer treatment-related cardiovascular toxicityValvular heart diseaseCardiac computed tomographyCardiac magnetic resonanceCardiac tumorsCardiovascular complicationsCardiovascular riskCalcium scoreHeart failureNoncancer patientsCardiovascular toxicityHeart diseaseCardiovascular diseaseCT scanComputed tomographyPatientsRadiation therapy treatmentTherapy treatmentDiseaseNew subspecialtyCardiac Magnetic Resonance in Cardio-Oncology Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization
O’Quinn R, Ferrari VA, Daly R, Hundley G, Baldassarre LA, Han Y, Barac A, Arnold A. Cardiac Magnetic Resonance in Cardio-Oncology Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization. JACC CardioOncology 2021, 3: 191-200. PMID: 34396324, PMCID: PMC8352183, DOI: 10.1016/j.jaccao.2021.04.011.Peer-Reviewed Original ResearchLeft ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity
Higgins AY, Arbune A, Soufer A, Ragheb E, Kwan JM, Lamy J, Henry M, Cuomo JR, Charifa A, Gallegos C, Hull S, Coviello JS, Bader AS, Peters DC, Huber S, Mojibian HR, Sinusas AJ, Kluger H, Baldassarre LA. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLOS ONE 2021, 16: e0246764. PMID: 33606757, PMCID: PMC7895343, DOI: 10.1371/journal.pone.0246764.Peer-Reviewed Original ResearchConceptsGlobal longitudinal strainImmune checkpoint inhibitorsLate gadolinium enhancementRecovery of LVEFLake Louise criteriaCheckpoint inhibitorsNormal LVEFAverage global longitudinal strainPresence of LGEAbnormal global longitudinal strainCardiac magnetic resonance imagingCorrect clinical contextEvaluation of myocarditisLeft ventricular dysfunctionVentricular ejection fractionDiagnosis of myocarditisLeft ventricular strainCardiac magnetic resonanceLeft ventricular myocardial strainOvert left ventricular dysfunctionVentricular myocardial strainMagnetic resonance imagingAtrial strainVentricular dysfunctionVentricular strain
2020
Cardiac Biventricular Metastasis From Renal Cell Carcinoma
Latifi AN, Ibe U, Arbune A, Kluger H, Baldassarre LA. Cardiac Biventricular Metastasis From Renal Cell Carcinoma. Cureus 2020, 12: e10870. PMID: 33178523, PMCID: PMC7652367, DOI: 10.7759/cureus.10870.Peer-Reviewed Original ResearchRenal cell carcinomaMetastatic renal cell carcinomaCardiac metastasisCell carcinomaRecurrent metastatic renal cell carcinomaCircumferential pericardial effusionSecondary cardiac tumorsAdvanced metastatic diseaseExtent of diseaseShortness of breathSite of involvementCardiac magnetic resonanceCardiac tumorsRespiratory failureMetastatic diseasePericardial effusionSystemic therapyBiventricular hypertrophyMultiple lesionsPrimary tumorPatient's diseaseTissue biopsiesMetastasisVentricular wallDisease
2019
The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics
Soufer A, Baldassarre LA. The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics. Current Treatment Options In Cardiovascular Medicine 2019, 21: 28. PMID: 31104180, DOI: 10.1007/s11936-019-0732-5.Peer-Reviewed Original ResearchCardiac magnetic resonanceCardiac toxicityCardiac magnetic resonance imagingNon-invasive workupImmune checkpoint inhibitorsSubclinical LV dysfunctionMyocardial tissue characteristicsCancer therapyPurpose of ReviewTheMagnetic resonance imagingCheckpoint inhibitorsLA fibrosisLV dysfunctionMicrocirculatory dysfunctionNon-invasive methodMagnetic resonanceCardiac structureResonance imagingMyocardial strainTissue characteristicsDysfunctionCancer therapeuticsTherapyToxicityFurther researchNuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods
Soufer A, Liu C, Henry ML, Baldassarre LA. Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods. Journal Of Nuclear Cardiology 2019, 27: 1210-1224. PMID: 30868378, DOI: 10.1007/s12350-019-01671-6.Peer-Reviewed Original ResearchConceptsCardiac toxicityPre-clinical cardiotoxicityCardiac magnetic resonanceNuclear cardiologyCardiovascular outcomesNon-invasive imagingCardiovascular toxicityChemotherapeutic agentsCancer treatmentEarly detectionCardiac imagingCancer therapyCancer therapeuticsCardiologyToxicityMagnetic resonanceTreatmentImagingEchocardiographyPatientsCardiotoxicityTherapyCancerSeverityCareUsing FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis
Sharp MB, Soufer A, Abdelmessih M, Rosenfeld LE, Baldassarre LA, Miller EJ. Using FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis. Journal Of Nuclear Cardiology 2019, 27: 688-690. PMID: 30737635, DOI: 10.1007/s12350-019-01640-z.Peer-Reviewed Original ResearchMyocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate
Gallegos C, Rottmann D, Nguyen VQ, Baldassarre LA. Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. European Heart Journal - Case Reports 2019, 3: yty149. PMID: 31020225, PMCID: PMC6439394, DOI: 10.1093/ehjcr/yty149.Peer-Reviewed Case Reports and Technical NotesLate gadolinium enhancementCardiovascular magnetic resonanceCardiac complicationsGadolinium enhancementAnti-programmed cell death protein 1 monoclonal antibodyCell death protein 1 monoclonal antibodyLeft ventricular ejection fractionNon-ischemic patternAcute heart failureCheckpoint inhibitor therapyRefractory cardiogenic shockCarotid artery dissectionCheckpoint inhibitor immunotherapyVentricular ejection fractionArea of myocardiumCardiac magnetic resonanceDirect histological correlationAreas of LGEArtery dissectionCardiogenic shockCheckpoint inhibitorsImmunosuppressive therapyVentricular dysfunctionEjection fractionHeart failure
2013
Mitral Apparatus Assessment by Delayed Enhancement CMR Relative Impact of Infarct Distribution on Mitral Regurgitation
Chinitz JS, Chen D, Goyal P, Wilson S, Islam F, Nguyen T, Wang Y, Hurtado-Rua S, Simprini L, Cham M, Levine RA, Devereux RB, Weinsaft JW. Mitral Apparatus Assessment by Delayed Enhancement CMR Relative Impact of Infarct Distribution on Mitral Regurgitation. JACC Cardiovascular Imaging 2013, 6: 220-234. PMID: 23489536, PMCID: PMC4048744, DOI: 10.1016/j.jcmg.2012.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnterior Wall Myocardial InfarctionChi-Square DistributionContrast MediaEchocardiography, Doppler, ColorEchocardiography, Doppler, PulsedFemaleHumansInferior Wall Myocardial InfarctionLogistic ModelsMagnetic Resonance Imaging, CineMaleMiddle AgedMitral ValveMitral Valve InsufficiencyMultivariate AnalysisMyocardiumOdds RatioPapillary MusclesPredictive Value of TestsProspective StudiesRegistriesRisk AssessmentRisk FactorsTime FactorsConceptsPapillary muscle infarctionAcute myocardial infarctionDelayed-enhancement cardiac magnetic resonanceMitral regurgitationInfarct distributionCulprit vesselMuscle infarctionPapillary musclesLateral wall infarctionLV end-diastolic diameterFirst acute myocardial infarctionGreater mitral regurgitationEnd-diastolic diameterCardiac magnetic resonanceMitral annular diameterLeft ventricular wallRight coronaryLeft circumflexInfarct patternsMultivariable analysisInfarct sizeMyocardial infarctionBasis of presenceWall injuryLV size